

Special Issue

Liquid Biopsy and Peripheral Immune Status in Cancer Therapy Response

Message from the Guest Editors

The shift to personalized oncology has already enabled longer remission and overall survival periods for many cancer patients. The primary tumor is not always accessible or adequate for performing all available biomarker analyses for patient sub-classification. Moreover, due to the rapid development of novel therapeutic interventions, the need for accurate biomarkers should be prioritized. Additionally, cancer development and therapeutic response are complex, multifunctional processes. Therefore, it is starting to become clear that combinatorial biomarkers may offer more accurate diagnostic, prognostic, and predictive results. This Special Issue on Liquid Biopsy and Peripheral Immune Status in Cancer Therapy Response will focus on the value of novel, easily accessible biomarkers in the response to all types of tumor therapy. We welcome submissions exploring the value of liquid biomarkers such as CTCs, exosomes, ctDNA, and blood immune cell populations.

Guest Editors

Dr. Galatea Kallergi

Dr. Anastasia Xagara

Dr. Constantin N. Baxevanis

Deadline for manuscript submissions

31 May 2026



Onco

an Open Access Journal
by MDPI



mdpi.com/si/255372

Onco
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
onco@mdpi.com

mdpi.com/journal/

[onco](https://mdpi.com/journal/onco)





Onco

an Open Access Journal
by MDPI



[mdpi.com/journal/
onco](https://mdpi.com/journal/onco)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Dr. Constantin N. Baxevanis

1. Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 11522 Athens, Greece
2. Flow Cytometry Unit, Section of Animal and Human Physiology, Department of Biology, National and Kapodistrian University of Athens, Panepistimiopolis, Ilisia, 15784 Athens, Greece

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.7 days after submission; acceptance to publication is undertaken in 4.8 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.